Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Rhythm Pharmaceuticals Inc (NQ: RYTM ) 51.01 -0.76 (-1.47%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 327,395 Open 51.24 Bid (Size) 51.01 (5) Ask (Size) 51.07 (3) Prev. Close 51.77 Today's Range 49.11 - 51.57 52wk Range 20.97 - 55.64 Shares Outstanding 61,133,765 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals September 18, 2024 Via Benzinga Rhythm Pharmaceuticals Announces New Employment Inducement Grants September 16, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Performance YTD +13.03% +13.03% 1 Month +11.01% +11.01% 3 Month +20.48% +20.48% 6 Month +27.37% +27.37% 1 Year +130.81% +130.81% More News Read More Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old August 26, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September August 26, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts July 25, 2024 Via Benzinga Analyst Expectations For Rhythm Pharmaceuticals's Future April 26, 2024 Via Benzinga Rhythm Pharmaceuticals Announces New Employment Inducement Grants August 13, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire RYTM Stock Earnings: Rhythm Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024 August 06, 2024 Via InvestorPlace Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update August 06, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old July 31, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity July 23, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 July 23, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces New Employment Inducement Grants July 11, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer July 08, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency June 28, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces New Employment Inducement Grants June 11, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 June 03, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference June 03, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome May 22, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces New Employment Inducement Grants May 09, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire The 3 Best Nasdaq Stocks to Buy in May 2024 May 07, 2024 Via InvestorPlace RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update May 07, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting May 06, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology April 29, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
